Literature DB >> 8372044

Central and peripheral mediation of hypothermia, tremor and salivation induced by muscarinic agonists in mice.

C Sánchez1, E Meier.   

Abstract

UNLABELLED: Hypothermia, tremor and salivation induced by muscarinic cholinergic agonists were studied in mice. Oxotremorine-M (quarternary agonist) shows high potency after intracerebroventricular administration, but the potency is low after subcutaneous administration. Oxotremorine potency (non-quarternary agonist) is higher after intracerebroventricular administration than after subcutaneous administration. Scopolamine and atropine (non-quarternary antagonists) antagonize oxotremorine-induced effects more potently after intracerebroventricular than subcutaneous administration. The quarternary antagonists N-methylscopolamine (NMS) and N-methylatropine (NMA) potently antagonize oxotremorine-induced salivation after both subcutaneous and intracerebroventricular administration. Hypothermia is antagonized partially (20-40%) over a large dose range after subcutaneous administration. In ex vivo receptor-binding studies of rat brain tissue, oxotremorine, scopolamine and atropine administered subcutaneously dose-dependently displace 3H-oxotremorine-M. Oxotremorine-M and NMS displace 3H-oxotremorine-M by 21% and 35%, respectively; NMA is ineffective. IN
CONCLUSION: Muscarinic cholinergic-mediated tremor is centrally regulated; hypothermia involves both a central and a peripheral component, the peripheral regulation being relatively less important than the central; central and peripheral regulation of salivation are equally important. Penetration of the blood brain barrier by oxotremorine-M and NMS is shown in the ex vivo binding studies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8372044     DOI: 10.1111/j.1600-0773.1993.tb01647.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  5 in total

1.  Reduced nicotinic receptor function in sympathetic ganglia is responsible for the hypothermia in the acetylcholinesterase knockout mouse.

Authors:  Minjeong Sun; C Justin Lee; Hee-Sup Shin
Journal:  J Physiol       Date:  2006-10-12       Impact factor: 5.182

2.  Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice.

Authors:  J Gomeza; H Shannon; E Kostenis; C Felder; L Zhang; J Brodkin; A Grinberg; H Sheng; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

3.  Central muscarinic receptor subtypes involved in pilocarpine-induced salivation, hypertension and water intake.

Authors:  T L Borella; L A De Luca; D S A Colombari; J V Menani
Journal:  Br J Pharmacol       Date:  2008-09-29       Impact factor: 8.739

4.  Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats.

Authors:  Mireille Basselin; Nelly E Villacreses; Ho-Joo Lee; Jane M Bell; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2007-06-12       Impact factor: 3.996

5.  In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine.

Authors:  G Howell; L West; C Jenkins; B Lineberry; D Yokum; R Rockhold
Journal:  BMC Pharmacol       Date:  2005-08-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.